Dose Modification of Subcutaneous Tocilizumab in Patients with Rheumatoid Arthritis.
作者信息
Best Jennie H, Abbass Ibrahim, Tominna Lenore, Reiss William
机构信息
Genentech, Inc., South San Francisco, CA.
出版信息
Am Health Drug Benefits. 2020 May;13(2):72-73.
Abstract
摘要
相似文献
1
Dose Modification of Subcutaneous Tocilizumab in Patients with Rheumatoid Arthritis.类风湿关节炎患者皮下注射托珠单抗的剂量调整
Am Health Drug Benefits. 2020 May;13(2):72-73.
2
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series.用托珠单抗治疗的类风湿关节炎患者的加速性皮下结节病：病例系列
J Med Case Rep. 2018 Jun 3;12(1):154. doi: 10.1186/s13256-018-1687-y.
3
Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.来自两项随机对照试验SUMMACTA和BREVACTA的类风湿关节炎患者皮下注射托珠单抗的药代动力学和药效学分析
J Clin Pharmacol. 2017 Apr;57(4):459-468. doi: 10.1002/jcph.826. Epub 2016 Nov 17.
4
Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.每周皮下注射托珠单抗单药治疗对每两周皮下注射托珠单抗应答不足的类风湿关节炎患者的长期安全性和疗效：SHINOBI 研究开放性扩展的结果。
Mod Rheumatol. 2019 Sep;29(5):767-774. doi: 10.1080/14397595.2018.1533514. Epub 2018 Dec 14.
5
A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.一项关于缩短类风湿关节炎患者皮下注射托珠单抗单药治疗给药间隔时间的随机、双盲、平行组III期研究，这些患者对每两周一次的皮下注射托珠单抗反应不足：12周双盲期结果
Mod Rheumatol. 2018 Jan;28(1):76-84. doi: 10.1080/14397595.2017.1332507. Epub 2017 Jun 16.
6
Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.皮下注射托珠单抗治疗类风湿关节炎。
Expert Rev Clin Immunol. 2016;12(2):103-14. doi: 10.1586/1744666X.2016.1127159. Epub 2016 Jan 28.
7
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.托珠单抗抑制白细胞介素-6受体对类风湿关节炎患者的影响（OPTION研究）：一项双盲、安慰剂对照的随机试验。
Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5.
8
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study.类风湿关节炎患者从静脉注射转换为皮下注射托珠单抗后的疗效：RoSwitch研究
Rheumatol Ther. 2019 Mar;6(1):61-75. doi: 10.1007/s40744-018-0138-y. Epub 2019 Jan 10.
9
The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation.托珠单抗对类风湿关节炎患者身体功能和生活质量的影响：一项系统的文献综述与解读
Open Access Rheumatol. 2012 Aug 9;4:87-92. doi: 10.2147/OARRR.S14563. eCollection 2012.
10
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.托珠单抗、甲氨蝶呤或二者联合治疗早期类风湿关节炎（U-Act-Early）：一项多中心、随机、双盲、双模拟、策略试验。
Lancet. 2016 Jul 23;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4. Epub 2016 Jun 7.
本文引用的文献
1
Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis.类风湿关节炎患者皮下注射托珠单抗的真实世界剂量调整模式
Am Health Drug Benefits. 2019 Dec;12(8):400-409.
2
Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.TNF 抑制剂和托珠单抗联合或不联合常规合成的疾病修饰抗风湿药物治疗生物初治类风湿关节炎患者的欧洲多中心观察性队列研究。
Semin Arthritis Rheum. 2020 Feb;50(1):17-24. doi: 10.1016/j.semarthrit.2019.06.020. Epub 2019 Jun 28.
3
4
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.至少使用一种生物制剂类改善病情抗风湿药后，托珠单抗对比 TNF 抑制剂单药或联合常规合成改善病情抗风湿药治疗类风湿关节炎患者的疗效：来自泛欧 TOCERRA 登记协作的分析。
Ann Rheum Dis. 2018 Sep;77(9):1276-1282. doi: 10.1136/annrheumdis-2017-212845. Epub 2018 May 5.
5
Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.类风湿关节炎患者对靶向免疫调节剂应答不足的经济负担。
J Manag Care Spec Pharm. 2018 Apr;24(4):344-352. doi: 10.18553/jmcp.2018.24.4.344.
6
Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.类风湿关节炎患者七种生物制剂的药物保留和停药原因 - ANSWER 队列研究。
PLoS One. 2018 Mar 15;13(3):e0194130. doi: 10.1371/journal.pone.0194130. eCollection 2018.
7
Association Between Glucocorticoid Exposure and Healthcare Expenditures for Potential Glucocorticoid-related Adverse Events in Patients with Rheumatoid Arthritis.糖皮质激素暴露与类风湿关节炎患者潜在糖皮质激素相关不良事件的医疗支出之间的关联。
J Rheumatol. 2018 Mar;45(3):320-328. doi: 10.3899/jrheum.170418. Epub 2018 Jan 15.
8
Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis.美国类风湿关节炎医疗费用：系统文献回顾和荟萃分析。
Arthritis Care Res (Hoboken). 2018 Oct;70(10):1431-1438. doi: 10.1002/acr.23512.
9
Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents.三种静脉注射药物治疗的类风湿关节炎患者剂量递增的发生率及其对生物制剂成本的影响。
J Comp Eff Res. 2017 Nov;6(8):671-682. doi: 10.2217/cer-2016-0090. Epub 2017 Aug 9.
10
Societal cost of rheumatoid arthritis patients in the US.美国类风湿关节炎患者的社会成本。
Curr Med Res Opin. 2010 Jan;26(1):77-90. doi: 10.1185/03007990903422307.
Zotero 插件